

Ongoing Regenerative Medicine Clinical Trials to Treat COVID-19 & Related Complications



Sponsors & Collaborators	Trial Countries	Phase	Anticipated Enrollment	Tech Type	Tech Sub-Type	Preliminary Results
Chinese Academy of Medical Sciences; The National Key Research and Development Program of China	China	Ph 1/2	60	CT	MSCs	Here
Beijing 302 Hospital; Innovative Precision Medicine Group; Wuhan Huoshenshan Hospital; Tianjin Haihe Hospital; VCANBIO Cell & Gene Engineering Corp; Shenzhen Third People's Hospital; Fifth Affiliated Hospital	China	Ph 1	20	CT	MSCs	n/a
Beijing 302 Hospital; VCANBIO CELL & GENE ENGINEERING CORP; Wuhan Huoshenshan Hospital; Tianjin Haihe Hospital; Shenzhen Third People's Hospital; Fifth Affiliated Hospital; Wuhan Union Hospital	China	Phase 2	60	CT	MSCs	n/a
Stem Cells Arabia	Jordan	Ph 1	5	CT	MSCs	n/a
Shenzhen Geno-Immune Medical Institute; Shenzhen Third People's Hospital; Shenzhen Second People's Hospital	China	Ph 1/2	100	CBIT	APC / Dendritic Cell	n/a
Shenzhen Geno-Immune Medical Institute; Shenzhen Third People's Hospital; Shenzhen Second People's Hospital	China	Ph 1	100	CBIT	APC / Dendritic Cell	n/a
Xinxiang Medical University; First Affiliated Hospital of Xinjiang Medical University	China	Ph 1	30	CBIT	NK Cells	Here
Chongqing Public Health Medical Center; Chongqing Sidemu Biotechnology	China	Ph 1/2	90	CBIT	NK Cells	n/a
Chinese Academy of Sciences; Beijing YouAn Hospital	China	Ph 1/2	9	CT	Other Stem Cells	n/a
Healios K.K.	Japan	Phase 2	30	CT	Other Stem Cells	n/a
Huangshi Hospital of Traditional Chinese Medicine	China	Ph 1	18	CT	MSCs	n/a
Renmin Hospital of Wuhan University; Beijing SH Bio-Tech Corporation; Utooth Biological Technology	China	Ph 1/2	20	CT	MSCs	n/a
Capricor	United States	CU / EA	n/a	CT	Other Stem Cells	Here
Puren Hospital; Shanghai University; Qingdao Co-orient Watson Biotechnology Group; Chinese Academy of Medical Sciences	China	Ph 1/2	30	CT	MSCs	n/a
Belfast Health and Social Care Trust; Queen's University, Belfast; Northern Ireland Clinical Trials Unit; NHS Blood and Transplant	United Kingdom	Ph 1/2	75	CT	MSCs	n/a
US Department of Defense; Harborview Injury Prevention and Research Center; Oregon Health and Science University; Vanderbilt University Medical Center; The University of Texas Health Science Center; University of Minnesota UCSF	United States	Ph 2	120	CT	MSCs	n/a
ZhiYong Peng; Tuohua Biological Technology; Zhongnan Hospital	China	Ph 2	10	CT	MSCs	n/a
Camillo Ricordi; University of Miami	United States	Ph 1/2	24	CT	MSCs	n/a
Royan Institute; Tehran University of Medical Sciences; Shahid Beheshti University of Medical Sciences	Iran	Ph 2/3	60	CT	MSCs	n/a
Chinese Academy of Sciences; Beijing YouAn Hospital	France	Ph 1/2	60	CT	MSCs	n/a
Red de Terapia Celular; Cytospin; University of Valladolid; Castilla-Leon Health Service; Hospital del Río Hortega; Instituto de Salud Carlos III	Spain	Ph 2	24	CT	MSCs	n/a
Athersys	United States	Ph 2/3	400	CT	Other Stem Cells	n/a
Icahn School of Medicine at Mount Sinai; Mesoblast, Inc.	United States	Ph 3	300	CT	MSCs	n/a
Mesoblast	United States	CU / EA	12	CT	MSCs	Here
Kerman University of Medical Sciences	Iran	Ph 2	10	CT	MSCs	n/a
Banc de Sang; Teixits	Spain	Ph 1/2	30	CT	MSCs	n/a
Puristem	Israel	CU / EA	7	CT	MSCs	Here

EA / CU – expanded access / compassionate use; CT = cell therapy; CBIT = cell-based immunotherapy; MSCs = mesenchymal stem cells; APC = antigen presenting cells; NK = natural killer

This dataset only includes those trials that are active, interventional, therapeutic, Phase 1-3 trials. Therapeutic candidates used under expanded access or compassionate use programs may not be included if not administered via a registered clinical trial.

Updated: May 8, 2020